Retail pharmacy drug sales in 13 major markets grew 5% overall US$ terms, during the 12 months to August 2007, reaching $406.57 billion, reports IMS Health's Retail Drug Monitor. The rate of increase remains unchanged since April 2006 (Marketletters passim).
The most striking change since the last set of figures reported in this publication (Marketletter September 24) has seen Japan's growth double to 2%, reaching $56.82 billion. In previous reports, the Japanese market, where IMS includes hospital sales in its study, had been declining.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze